Blood pressure and endocrine effects of single doses of cs‐866, a novel angiotensin ii antagonist, in salt‐restricted hypertensive patients

Journal of Hypertension

Volumn 15, Issue 12, 1997, Pages 1809-1812

  Püchler, Kurt ^a   Nussberger, Jürg ^b   Laeis, Petra ^b   Witte, Peter U ^b   Brunner, Hans R ^b  

^a Sankyo Europe GmbH   (United Kingdom)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiotensin II antagonist; Blood pressure; CS 866; Hypertensive patients; Plasma angiotensin II; Plasma renin activity

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN II ANTAGONIST; OLMESARTAN; RENIN; UNCLASSIFIED DRUG;

ADULT; BORDERLINE HYPERTENSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RESTRICTION;

EID: 0031459193     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/00004872-199715120-00094     Document Type: Article

References (14)

1. Burnier M, Waeber B, Brunner HR: The advantages of angiotensin II antagonism. J Hypertens 1994, 12 (suppl 2):7-15.
2. MacFadyen RJ, Lee KR, Reid IL: Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. Br J Clin Pharmacol 1991, 31:1-13.
3. Cody R: Renin inhibition: the beginning of the fourth epoch. Circulation 1992, 85:362-364.
4. Messerli FH, Weber MA, Brunner HR: Angiotensin II receptor inhibition. A new therapeutic principle. Arch Intern Med 1996, 156:1957-1965.
5. Company communication, Sankyo: CS-866: Pharmaprojects. Richmond, Surrey: PJB Publications Ltd; 1996.
6. Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, Koike H: Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995, 285:181-188.
7. MacFadyen RJ, Elliott HL, Meredith PA, Reid JL: Haemodynamic and hormonal response to low dose enalapril in salt-depleted normotensive men. Br J Clin Pharmacol 1993, 35:299-301.
8. Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL: Dose ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-depleted normal man. J Cardiovasc Pharmacol 1993, 21:732-738.
9. MacFayden RJ, Jones CR, Doig IK, Birnbock H, Reid JL: Responses to an orally active renin inhibitor, remikiren (Ro 42-5892) after controlled salt depletion in humans. J Cardiovasc Pharmacol 1995, 25:S347-S353.
10. Nussberger J, Fasanella d'Amore I, Porchet M, Waeber B, Brunner DB, Brunner HR, et al.: Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol 1987, 9:39-44.
11. Nussberger J, Keller I, Waeber B, Brunner HR: Angiotensin II measurement with high-affinity monoclonal antibodies. J Hypertens 1988, 6 (suppl 4):S424-S425.
12. Burnier M, Waeber B, Brunner HR: Clinical pharmacology of the angiotensin II receptor losartan potassium in healthy subjects. J Hypertens 1995, 13 (suppl 1):523-528.
13. MacFadyen RJ, Less KR, Ried JL: Responses to low dose peridonprilat infusion in salt-depleted/salt-repleted normotensive volunteers. Br J Clin Pharmacol 1994, 38:329-334.
14. Delacrétaz E, Nussberger J, Püchler K, Wood AJ, Robinson PR, Waeber B, et al.: Value of different clinical and biological correlates to assess angiotensin converting enzymes inhibition. J Cardiovasc Pharmacol 1994, 24:479-485.